CinCor Pharma, Inc. (CINC)
CinCor Pharma, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $29.06, up 0.00% on the session, giving a market capitalisation of $1.27B. On trailing twelve-month figures it carries a trailing P/E of -20.46, a net margin of 0.0%. Its beta of 0.00 implies it has historically moved less than the broad market.
CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions. At the core of its pipeline is CIN-107, an investigational compound currently undergoing Phase II clinical trials for indications such as hypertension, primary aldosteronism, and various other cardio-renal disorders. Additionally, CIN-107 is in Phase I clinical evaluation for its potential in treating chronic kidney diseases. The company holds a significant licensing agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. Established in 2018, CinCor Pharma, Inc. maintains its principal operations in Boston, Massachusetts.
CinCor Pharma, Inc. is most often compared with the following Healthcare names: